Mitochondrial Toxicity of Antiviral Drugs: A Challenge to Accurate Diagnosis

Drug-Induced Mitochondrial Dysfunction

Volumn , Issue , 2008, Pages 473-491

  De Baar, Michel P ^a,b   De Ronde, Anthony ^b  

^a Octo Plus NV   (Netherlands)

^b Primagen   (Netherlands)

Author keywords

Antiviral drugs and mitochondrial toxicity; Hyperlactatemia and mitochondrial dysfunction; MtDNA biomarker predicting adverse effect

Indexed keywords

EID: 65549134683     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470372531.ch20     Document Type: Chapter

References (127)

1. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002;16(5):737-745.
2. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003;26(2):195-207.
3. Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripheral Nerv Syst. 2001;6(1):14-20.
4. Keilbaugh SA, Hobbs GA, Simpson MV. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycy tidinetoxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Mol Pharmacol. 1993;44(4):702-706.
5. Rabing CE, Stegger M, Jensen-Fangel S, Laursen AL, Ostergaard L. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis. 2004;39(9):1371-1379.
6. Arnaudo E, Dalakas M, Shanske S, Moraes CT, Dimauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991;337(8740):508-510.
7. Chariot P, Drogou I, Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999;30(1):156-160.
8. Grau JM, Casademont J. HIV or zidovudine myopathy? Neurology. 1994;44(2): 361-364.
9. Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis. 2003;45(4):305-318.
10. Masanes F, Barrientos A, Cebrian M, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci. 1998;159(2):226-228.
11. Bleeker-Rovers CP, Kadir SW, van Leusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med. 2000;57(5):190-193.
12. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis. 2000;31(1):167-169.
13. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43(3):365-372.
14. Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis. 1995;21(4):973-976.
15. Pao D, Watson C, Peters B, Lucas SB, Miller RF. Hyperlactataemia and hepatic steatosis: mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. Sex Transm Infect. 2001;77(5):381-384.
16. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 2005;19(6):356-365.
17. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5(1):36-43.
18. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44(1 suppl):S132-S139.
19. Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis. 2003;23(2):167-172.
20. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33(11):1931-1937.
21. Brinkman K. Evidence for mitochondrial toxicity: lactic acidosis as proof of concept. J HIV Ther. 2001;6(1):13-16.
22. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis. 2002;15(1):23-29.
23. Khouri S, Cushing H. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy. AIDS Read. 2000;10(10):602-606.
24. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis. 2000;30(1): 198-200.
25. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000;11(9):611-616.
26. Baker WC. Impaired glucose metabolism and HIV: an overview. Adv Nurse Pract. 2003;11(4):47-49.
27. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45(1):111-119.
28. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292(6):E1666-E1673.
29. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423-1430.
30. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS. 2001;12(9):555-562.
31. Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med. 2001;2(3):166-173.
32. Moyle G. Lipodystrophy: lack of agreement on definition and etiology presents a challenge to research and therapy. AIDS Read. 2002;12(10):438, 440-438, 442.
33. ter Hofstede HJ, Burger DM, Koopmans PP. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. Neth J Med. 2003;61(12):393-403.
34. Tozser J. HIV inhibitors: problems and reality. Ann N Y Acad Sci. 2001;946:145-159.
35. Walker UA, Brinkman K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction? HIV Med. 2001;2(3):163-165.
36. Wanke C. Pathogenesis of HIV-associated lipodystrophy. AIDS Clin Care. 2000;12(12):100.
37. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184): 1112-1115.
38. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995; 1(5):417-422.
39. Bendele RA, Richardson FC. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum Pathol. 2002;33(5):574.
40. Buffet M, Schwarzinger M, Amellal B, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol. 2005;33(1):60-64.
41. Chabi B, Mousson dC, Duborjal H, Issartel JP, Stepien G. Quantification of mitochondrial DNA deletion, depletion, and overreplication: application to diagnosis. Clin Chem. 2003;49(8):1309-1317.
42. Church JA, Mitchell WG, Gonzalez-Gomez I, et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr. 2001;138(5):748-751.
43. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest. 2001;81(11):1537-1544.
44. Mancuso M, Filosto M, Bonilla E, et al. Mitochondrial myopathy of childhood associated with mitochondrial DNA depletion and a homozygous mutation (T77M) in the TK2 gene. Arch Neurol. 2003;60(7):1007-1009.
45. Mancuso M, Salviati L, Sacconi S, et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology. 2002;59(8):1197-1202.
46. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol. 2003;70(4):497-505.
47. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17(9):1329-1338.
48. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003;8(4):323-331.
49. Petit C, Mathez D, Barthelemy C, et al. Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immune Defic Syndr. 2003;33(4):461-469.
50. Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med. 2004;5(1):11-14.
51. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001;32(7):734-740.
52. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther. 2006;11(1):25-34.
53. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther. 2003;8(5):463-470.
54. Banasch M, Goetze O, Knyhala K, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS. 2006;20(11):1554-1556.
55. McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr. 2007; in press (advanced online publication 30 May).
56. Sutinen J, Walker UA, Sevastianov K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther. 2007;12(1):97-105.
57. UNAIDS. AIDS epidemic update December 2006. WHO Library Cataloguing-in Publication Data. 2006.
58. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-1263.
59. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis. 2003;23(2):173-182.
60. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;59(3):342-346.
61. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15(18):2407-2414.
62. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(3):F25-F32.
63. McComsey G. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. AIDS Rev. 2002;4(3):140-147.
64. Chalmers AC, Greco CM, Miller RG. Prognosis in AZT myopathy. Neurology. 1991;41(8):1181-1184.
65. Miro O, Pedrol E, Cebrian M, et al. Skeletal muscle studies in patients with HIV-related wasting syndrome. J Neurol Sci. 1997;150(2):153-159.
66. UNAIDS. Recommendations for first line therapy. http://www.who.int/hiv/topics/arv/en/. 2007.
67. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16(10):1341-1349.
68. Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, Bruun JN. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. HIV Med. 2006;7(1):53-58.
69. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther. 2005;10 (Suppl 2):M83-M89.
70. Heath KV, Montaner JS, Bondy G, Singer J, O'Shaughnessy MV, Hogg RS. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets. 2003;4(1):13-22.
71. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr. 2002;30(4): 440-447.
72. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther. 2006;11(6):729-740.
73. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361(9359):726-735.
74. Polo R, Verdejo J, Martinez-Rodriguez S, Madrigal P, Gonzalez-Munoz M. Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr. 2000;25(3):284-286.
75. Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet. 2003;362(9397):1758-1760.
76. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS. 2006;20(5):675-684.
77. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antivir Res. 2002;54(1):37-45.
78. de Baar MP, de Rooij ER, Smolders KGM, van Schijndel HB, Timmermans EC, Bethell RC. Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. Antivir. Res. 2007;76(1):68-74.
79. Lewis W, Gonzalez B, Chomyn A, Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest. 1992;89(4):1354-1360.
80. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 2002;16(15):2013-2018.
81. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS. 2003;17(1):121-123.
82. Yamanaka H, Gatanaga H, Kosalaraksa P, et al. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis. 2007;195(10):1419-1425.
83. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr. 2002;30(3):271-277.
84. Cherry CL, Nolan D, James IR, et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr. 2006;42(4):435-440.
85. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 2005;19(1):15-23.
86. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346(11):811-820.
87. Timmermans EC, Tebas P, Ruiter JP, Wanders RJ, de Ronde A, de Baar MP. Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. Clin Chem. 2006;52(6):979-987.
88. Casula M, Weverling GJ, Wit FW, et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis. 2005;192(10):1794-1800.
89. Casula M, van d, V,Wit FW, Nievaard MA, Reiss P. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition. HIV Med. 2007;8(1):32-37.
90. Ben Romano R, Rudich A, Etzion S, et al. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther. 2006;11(8):1051-1060.
91. Nerurkar PV, Pearson L, Frank JE, Yanagihara R, Nerurkar VR. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production. Cell Mol Biol (Noisy-Le-Grand). 2003;49(8):1205-1211.
92. Hertel J, Struthers H, Horj CB, Hruz PW. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem. 2004;279(53): 55147-55152.
93. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS. 2002;16(6):859-863.
94. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359(9311):1026-1031.
95. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50(6):1378-1388.
96. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275(27):20251-20254.
97. Nolan D, John M, Mallal S. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir Ther. 2001;6(3):145-160.
98. Rudich A, Vanounou S, Riesenberg K, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes. 2001;50(6):1425-1431.
99. Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol. 2003;149(2):229-236.
100. de la Asuncion JG, del Olmo ML, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria: prevention by antioxidant vitamins. J Clin Invest. 1998;102(1):4-9.
101. de la Asuncion JG, del Olmo ML, Gomez-Cambronero LG, Sastre J, Pallardo FV, Vina J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci. 2004;76(1):47-56.
102. Skuta G, Fischer GM, Janaky T, et al. Molecular mechanism of the short-term cardiotoxicity caused by 2',3'-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions. Biochem Pharmacol. 1999;58(12): 1915-1925.
103. Szabados E, Fischer GM, Toth K, et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med. 1999;26(3-4):309-317.
104. Macho A, Calzado MA, Jimenez-Reina L, Ceballos E, Leon J, Munoz E. Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis: biochemical mechanisms. Oncogene. 1999;18(52):7543-7551.
105. Olivetta E, Pietraforte D, Schiavoni I, Minetti M, Federico M, Sanchez M. HIV-1 Nef regulates the release of superoxide anions from human macrophages. Biochem J. 2005;390(pt 2):591-602.
106. Gulow K, Kaminski M, Darvas K, Suss D, Li-Weber M, Krammer PH. HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. J Immunol. 2005;174(9):5249-5260.
107. Delchev SD, Georgieva KN, Koeva YA, Atanassova PK. Bcl-2/Bax ratio, mitochondrial membranes and aerobic enzyme activity in cardiomyocytes of rats after submaximal training. Folia Med (Plovdiv.) 2006;48(2):50-56.
108. Eissing T, Waldherr S, Allgower F, Scheurich P, Bullinger E. Response to bistability in apoptosis: roles of Bax, Bcl-2, and mitochondrial permeability transition pores. Biophys J. 2007;92(9):3332-3334.
109. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondriondependent apoptosis by Bcl-2 subfamilies. Nat Cell Biol. 2006;8(12):1348-1358.
110. Matarrese P, Gambardella L, Cassone A, Vella S, Cauda R, Malorni W. Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J Immunol. 2003;170(12):6006-6015.
111. Metrailler-Ruchonnet I, Pagano A, Carnesecchi S, Ody C, Donati Y, Barazzone AC. Bcl-2 protects against hyperoxia-induced apoptosis through inhibition of the mitochondria-dependent pathway. Free Radic Biol Med. 2007;42(7):1062-1074.
112. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulo lylmethane)-induced apoptosis in prostate cancer. Int J Oncol. 2007;30(4):905-918.
113. Simbula G, Columbano A, Ledda-Columbano GM, et al. Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis. 2007;12(1):113-123.
114. Somma F, Tuosto L, Montani MS, Di Somma MM, Cundari E, Piccolella E. Engagement of CD4 before TCR triggering regulates both Bax-and Fas (CD95)-mediated apoptosis. J Immunol. 2000;164(10):5078-5087.
115. Hammond EL, Sayer D, Nolan D, et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol. 2003;27(1):97-110.
116. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(3):716-723.
117. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991;39(5):625-628.
118. Gahan ME, Miller F, Lewin SR, et al. Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. J Clin Virol. 2001;22(3):241-247.
119. Cossarizza A, Pinti M, Moretti L, et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis. 2002;185(3):299-305.
120. Chene G, Amellal B, Pedrono G, et al. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy. AIDS Res Hum Retroviruses. 2007;23(1):54-61.
121. Maagaard A, Holberg-Petersen M, Kollberg G, Oldfors A, Sandvik L, Bruun JN. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther. 2006;11(5):601-608.
122. Gourlain K, Amellal B, Ait AZ, Dupin N, Katlama C, Calvez V. Quantitative analysis of human mitochondrial DNA using a real-time PCR assay. HIV Med. 2003;4(3):287-292.
123. Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis. 2003;16(1):5-10.
124. Gallant J, Staszewski S, Pozniak A, et al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naive patients: a 48 week interim analysis. Abstract. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Sept. 27-30, 2002.
125. Casula M, Vrisekoop N, Wit FW, et al. Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation. J Infect Dis. 2007;196(3):371-376.
126. Casula M, Bosboom-Dobbelaer I, Smolders K, et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis. 2005;191(9):1468-1471.
127. Polo R, Martinez S, Madrigal P, Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr. 2003;34(1):32-36.